Most Read Articles
Jairia Dela Cruz, 05 Oct 2020
Drinking more than two cups of coffee per day may just be the intervention that prevents hundreds of thousands of liver disease‐related deaths globally, a study reports.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Stephen Padilla, Yesterday
Use of systemic corticosteroids does not reduce in-hospital mortality for patients with severe or critical coronavirus disease (COVID-19), which is in stark contrast to that observed in the RECOVERY clinical trial, according to a study in Wuhan, China.

Pain, self-reported swollen joints tied to flares in rheumatoid arthritis

22 Sep 2020

Self-reported flares are common and generally managed by analgesics in rheumatoid arthritis (RA), according to a study. In addition, they are substantiated higher activity measures, independently associated with pain and patient-reported swollen joints, and linked to treatment intensification.

The investigators examined consecutive RA patients with 28-joint count Disease Activity Score based on C-reactive protein (DAS28-CRP) <3.2 and no swollen joints at baseline, month 6, and month 12. Their assessments included joint counts, DAS28-CRP, visual analogue scale–evaluator’s global assessment (EGA), and patient-reported outcomes (PROs).

Patients completed the Flare Assessment in Rheumatoid Arthritis and RA Flare Questionnaire and disclosed self-management strategies every 3 months. Finally, the investigators compared flaring and nonflaring patients and explored longitudinal associations between self-reported flare status and disease activity, PRO, and treatment escalation.

Eighty patients with RA (mean age, 63 years; 74 percent females; disease duration, 11 years; baseline DAS28-CRP, 1.9) were included, of whom 64 (80 percent) reported flare at least once during 12 months. More than half (55 percent) of these flares lasted less than 1 week. Analgesics (50 percent) and restricted activities (38 percent) were the common self-management strategies. Patients with flare, compared to those without, had consistently higher disease activity measures and PRO.

Results from a partly adjusted model indicated the association of flares with patient-reported swollen and tender joint counts, disease activity measures, and all flare domains. Moreover, fully adjusted analyses revealed the independent association of present flare with pain (odds ratio [OR], 1.85, 95 percent confidence interval [CI], 1.34–2.60), patient-reported swollen joints (OR, 1.18, 95 percent CI, 1.03–1.36), and higher EGA (OR, 1.15, 95 percent CI, 1.04–1.28). Present flare also correlated with treatment escalation (p≤0.001).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 05 Oct 2020
Drinking more than two cups of coffee per day may just be the intervention that prevents hundreds of thousands of liver disease‐related deaths globally, a study reports.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Stephen Padilla, Yesterday
Use of systemic corticosteroids does not reduce in-hospital mortality for patients with severe or critical coronavirus disease (COVID-19), which is in stark contrast to that observed in the RECOVERY clinical trial, according to a study in Wuhan, China.